These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32917574)

  • 21. The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial.
    Saber-Moghaddam N; Nodeh MM; Ghavami V; Rahimi H; Azimi SA; Seddigh-Shamsi M; Kamandi M; Allahyari A; Shariatmaghani SS; Elyasi S; Arasteh O
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4355-4364. PubMed ID: 38095652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections.
    Hsu A; Matera R; Vieira K; Reagan JL; Farmakiotis D
    Support Care Cancer; 2021 Feb; 29(2):707-712. PubMed ID: 32435969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
    Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
    PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
    Aldoss I; Dadwal S; Zhang J; Tegtmeier B; Mei M; Arslan S; Al Malki MM; Salhotra A; Ali H; Aribi A; Sandhu K; Khaled S; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Blood Adv; 2019 Dec; 3(23):4043-4049. PubMed ID: 31816059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia.
    Wang ST; Chou CH; Chen TT; Lin CC; Bai LY; Yeh SP; Ho MW; Lien MY
    Front Cell Infect Microbiol; 2022; 12():1012334. PubMed ID: 36530436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
    Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
    Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
    Machherndl-Spandl S; Vockenhuber T; Binder M; Weltermann A; Apfalter P; Lass-Flörl C; Girschikofsky M
    Leuk Lymphoma; 2022 Oct; 63(10):2330-2335. PubMed ID: 35561263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan.
    Lin GL; Chang HH; Lu CY; Chen CM; Lu MY; Lee PI; Jou ST; Yang YL; Huang LM; Chang LY
    J Microbiol Immunol Infect; 2018 Apr; 51(2):251-259. PubMed ID: 28089099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
    Tey A; Shaw B; Cardamone L; Shepherd S; Paul E; Rogers B; Shortt J
    Eur J Haematol; 2021 Aug; 107(2):181-189. PubMed ID: 33829584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
    Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
    J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    On S; Rath CG; Lan M; Wu B; Lau KM; Cheung E; Alegria W; Young R; Tan M; Kim C; Phun J; Patel N; Mannis G; Logan AC; Kennedy V; Goodman A; Taplitz RA; Young PA; Wen R; Saunders IM
    Br J Haematol; 2022 Apr; 197(1):63-70. PubMed ID: 35174480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
    Rodríguez-Veiga R; Montesinos P; Boluda B; Lorenzo I; Martínez-Cuadrón D; Salavert M; Pemán J; Calvillo P; Cano I; Acuña E; Villalba A; Piñana JL; Sanz J; Solves P; Senent L; Vicente A; Sempere A; Cervera J; Barragán E; Jarque I; Torres A; Sanz MA; Sanz GF
    Ann Hematol; 2019 Sep; 98(9):2081-2088. PubMed ID: 31240471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
    White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
    J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
    Michallet M; Sobh M; Morisset S; Deloire A; Raffoux E; de Botton S; Caillot D; Chantepie S; Girault S; Berthon C; Bertoli S; Lepretre S; Leguay T; Castaigne S; Marolleau JP; Pautas C; Malfuson JV; Veyn N; Braun T; Gastaud L; Suarez F; Schmidt A; Gressin R; Bonmati C; Celli-Lebras K; El-Hamri M; Ribaud P; Dombret H; Thomas X; Bergeron A
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):311-318. PubMed ID: 34895843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.